New drug formulations of colony-stimulating factors in oncohematology

Colony Stimulating Factors: Regulation of Production

Life span of mature blood cells is ephemeral, reqUIrIng hematopoiesis throughout life. A complex network of hematopoietic progenitor cells and cytokines maintain an enormous daily production of granulocytes, monocytes, erythrocytes, platelets, and lymphocytes. This population of hematopoietic cells must be able to respond rapidly to changing needs such as bleeding, infections, cancer, or exposu...

Mesenchymal Stem Cells with Granulocyte Colony-Stimulating Factor Reduce Stress Oxidative Factors in Parkinson\'s Disease

Background: Recent studies have shown that bone marrow mesenchymal stem cells (BMSCs) have a putative ability to promote neurogenesis and produce behavioral and functional improvement. Our previous study demonstrated that co-treatment of granulocyte colony-stimulating factor (G-CSF) and BMSCs have beneficial effects on Parkinson's models. The main purpose of this research was to investigate the...

Colony stimulating factors and macrophage heterogeneity

Macrophages or mononuclear phagocytes are heterogeneous populations present throughout the body which can adapt quite dramatically to the surrounding milieu, both in the steady state and during immune/inflammatory responses. To assist in our understanding of this diversity, they have been classified into polarization or “activation” states, termed M1 and M2, respectively. This in vitro classifi...

Haemopoietic colony stimulating factors for preterm neonates.

Bacterial and fungal sepsis is a major cause of morbidity and mortality in neonates. Infection rates are high in infants treated in intensive care units, with the highest rates, of around 30%, occurring in extremely immature preterm neonates. A survey of neonatal infection at Yale University, ongoing since 1928, has documented a decline in neonatal septic deaths commensurate with the establishm...

Colony-stimulating factors in the pathogenesis and treatment of disease.